Immunoadsorption Treatment for Post-COVID Fatigue
Author Information
Author(s): Stein Elisa, Heindrich Cornelia, Wittke Kirsten, Kedor Claudia, Rust Rebekka, Freitag Helma, Sotzny Franziska, Krüger Anne, Tölle Markus, Grabowski Patricia, Scheibenbogen Carmen, Kim Laura
Primary Institution: Charité - Universitätsmedizin Berlin
Hypothesis
Immunoadsorption will lead to clinical improvement in post-COVID ME/CFS patients four weeks after treatment.
Conclusion
Immunoadsorption may improve symptoms in post-COVID ME/CFS patients.
Supporting Evidence
- 70% of patients showed a clinically meaningful improvement in physical functioning.
- Immunoglobulin G levels decreased by 79% after treatment.
- Patients reported lasting improvements in fatigue and pain.
- Significant improvements in autonomic symptoms were observed.
Takeaway
This study found that a special treatment called immunoadsorption can help people who feel very tired after having COVID-19 feel better.
Methodology
This was a pre-post study with 20 patients treated with five immunoadsorption sessions, measuring changes in health-related quality of life and symptoms over six months.
Potential Biases
Potential bias due to the observational nature of the study and lack of a control group.
Limitations
The study had a small sample size and was non-controlled, which may limit the generalizability of the findings.
Participant Demographics
The cohort included 20 patients, 7 male and 13 female, with a median age of 40 years.
Statistical Information
P-Value
p<0.001
Confidence Interval
CI: 13.41–26.16
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website